Your browser doesn't support javascript.
loading
A Potent and Selective AMPK Activator That Inhibits de Novo Lipogenesis.
Gómez-Galeno, Jorge E; Dang, Qun; Nguyen, Thanh H; Boyer, Serge H; Grote, Matthew P; Sun, Zhili; Chen, Mingwei; Craigo, William A; van Poelje, Paul D; MacKenna, Deidre A; Cable, Edward E; Rolzin, Paul A; Finn, Patricia D; Chi, Bert; Linemeyer, David L; Hecker, Scott J; Erion, Mark D.
Afiliación
  • Gómez-Galeno JE; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Dang Q; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Nguyen TH; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Boyer SH; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Grote MP; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Sun Z; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Chen M; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Craigo WA; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • van Poelje PD; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • MacKenna DA; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Cable EE; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Rolzin PA; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Finn PD; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Chi B; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Linemeyer DL; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Hecker SJ; Metabasis Therapeutics, Inc., La Jolla, California 92037.
  • Erion MD; Metabasis Therapeutics, Inc., La Jolla, California 92037.
ACS Med Chem Lett ; 1(9): 478-82, 2010 Dec 09.
Article en En | MEDLINE | ID: mdl-24900234
ABSTRACT
AMP-activated protein kinase (AMPK) is a heterotrimeric kinase that regulates cellular energy metabolism by affecting energy-consuming pathways such as de novo lipid biosynthesis and glucose production as well as energy-producing pathways such as lipid oxidation and glucose uptake. Accordingly, compounds that activate AMPK represent potential drug candidates for the treatment of hyperlipidemia and type 2 diabetes. Screening of a proprietary library of AMP mimetics identified the phosphonic acid 2 that bears little structural resemblance to AMP but is capable of activating AMPK with high potency (EC50 = 6 nM vs AMP EC50 = 6 µM) and specificity. Phosphonate prodrugs of 2 inhibited de novo lipogenesis in cellular and animal models of hyperlipidemia.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: ACS Med Chem Lett Año: 2010 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: ACS Med Chem Lett Año: 2010 Tipo del documento: Article